Trial builds on positive Phase 1 study that showed DT-101 was well tolerated and demonstrated target engagement Cardiff, United Kingdom – 2 October 2025 – Draig Therapeutics (“Draig”), a ...
Draig Therapeutics (Draig), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, announced that it will initiate a phase 2 study of DT-101, a next-generation AMPA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results